RecruitingPhase 1Phase 2NCT07038096
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment
350 participants
Start Date
Sep 23, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria5
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age.
- Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- Life expectancy \> 3 months.
Exclusion Criteria1
- The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Interventions
DRUGZG006
ZG006 will be administered as an intravenous (IV) infusion.
DRUGZG005
ZG005 will be administered as an intravenous (IV) infusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07038096
Related Trials
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT0715517416 locations
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT0678013745 locations
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT0701026353 locations
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT0625726424 locations
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210230 locations